Manufacturing and Importation Authorisation
Manufacturing and Importation Authorisation document
Adjuvant GMP certificates (English)
Language: English
Format: PDF
File size: 267.0 KB
Products
Featured
Alhydrogel™
One of the most widely used vaccine adjuvants, Alhydrogel is an aluminium-based adjuvant used in clinically-approved vaccines that can elicit effective Th2 immune responses.
.jpg&mn=healthcare&w=768&xr=0&yr=0&xfp=6&yfp=6&hash=A29CEF82F5BE8078AFF6628F0576AD4019C138999FEC74AA)
Featured
Adju-Phos™
Well-established as a common component in a variety of vaccines, Adju-Phos is an aluminium-based adjuvant that induces strong Th2 immune responses.
Featured
Quil-A™
A versatile immunostimulatory saponin that’s widely used as a potent veterinary adjuvant, Quil-A can work against both intra- and extra-cellular pathogens, stimulating innate and Th-mediated adaptive...
Featured
QS 21
*sample can be ordered for investigational use only* A powerful immunostimulatory saponin that acts as a potent vaccine adjuvant, QS 21 can stimulate both cell-mediated (Th1) and humoral (Th2)...
Featured
AlhydroVet™
AlhydroVet is an aluminium hydroxide gel product specifically manufactured for use as an adjuvant in veterinary vaccines.
Featured
3D(6-acyl)-PHAD™
Immunostimulatory and highly purified, 3D(6-acyl)-PHAD activates TLR4 to induce proinflammatory cytokines and T-cells.
Featured
CAF01®
Part of our new generation of adjuvants, CAF01 is a liposomal adjuvant formulation that offers excellent long-term stability and drives both humoral and cellular immune responses.
Featured
CAF09b®
A novel liposomal adjuvant used in cancer immunotherapy trials, CAF09b has the capacity to facilitate the production of CD8+ T-cells.
Featured
PHAD™
Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells.
Featured
3D-PHAD™
Highly pure, safe, and chemically stable, 3D-PHAD stimulates the immune system through the activation of TLR4, leading to the production of proinflammatory cytokines, CD4+ and CD8+ T-cells.